In this edition of The Upside, Lou Basenese sits down with Amir F. Heshmatpour, CEO of NeOnc Technologies Holdings, Inc., a biotech developing a novel approach to treating aggressive brain cancers. NeOnc’s lead therapy is designed to deliver cancer-fighting compounds directly to the brain through a non-invasive intranasal pathway – bypassing the blood-brain barrier that limits most drugs. The discussion explores why this delivery strategy could be a breakthrough for glioblastoma and other hard-to-treat brain tumors, and why upcoming clinical milestones may be critical for investors.